Vaccination using neoantigen peptides-loaded (autologous) dendritic cells
Sponsors
Tanigawa Keishi
Conditions
Malignant tumor (except leukemia)
Phase 2
Safety assessment of neoantigen peptides-loaded dendritic cell vaccination therapy.
Active, not recruitingJPRN-jRCTc030190183
Start: 2018-08-06Target: 20Updated: 2026-06-29
Dendritic cell therapy based on nepantigen-gene analysis
RecruitingJPRN-jRCTc030210026
Start: 2021-04-01Target: 30Updated: 2026-06-29